stockrow
Monday 9 November 2026
Export CABA’s income statement to Excel — free account
Cabaletta Bio, Inc.
CABA- EPS
- +53.4%
- Free cash flow
- −35.7%
Quarter to June 2026, against a year earlier
1.30
0.02
+1.56%
Follow CABA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 56 | — | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | 0 | (12) | (17) | (33) | (46) | (53) | (68) | (116) | (168) | (181) | +125.6% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (12) | (17) | (33) | (46) | (53) | (68) | (116) | (168) | (181) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (0.01) | (10.86) | (4.07) | (1.44) | (1.80) | (1.81) | (1.65) | (2.34) | (2.10) | (1.57) | +95.1% | ||||||
| Cash flow | — | 0.00 | (4.15) | (3.69) | (1.54) | (1.60) | (1.78) | (1.37) | (1.80) | (1.64) | (1.02) | n/m | ||||||
| Capex | — | 0.00 | 0.00 | (0.16) | (0.04) | (0.05) | (0.09) | (0.02) | (0.05) | (0.02) | 0.00 | n/m | ||||||
| Free cash flow | — | 0.00 | (4.15) | (3.85) | (1.57) | (1.65) | (1.88) | (1.38) | (1.84) | (1.66) | (1.02) | n/m | ||||||
| Book value | — | (0.01) | 29.56 | 31.83 | 6.29 | 5.52 | 4.02 | 6.03 | 3.11 | 1.40 | 1.39 | n/m | ||||||
| Shares, m | — | 24 | 1 | 4 | 17 | 21 | 26 | 39 | 49 | 80 | 111 | +16.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (16) | (27) | (34) | (46) | (54) | (88) | (131) | (154) | +61.1% | |||||
| Capex | — | — | — | (1) | (1) | (1) | (2) | (1) | (2) | (1) | (1) | +10.0% | ||||||
| Free cash flow | — | — | (5) | (17) | (27) | (35) | (49) | (54) | (90) | (132) | (154) | +61.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | 33 | 137 | 108 | 116 | 99 | 228 | 140 | 89 | 191 | n/m | |||||
| Net debt | — | 0 | (33) | (136) | (109) | (122) | (107) | (241) | (164) | (134) | (225) | +337.2% | ||||||
| Shareholders’ equity | — | 0 | 33 | 138 | 110 | 118 | 105 | 236 | 152 | 112 | 211 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (1.46) | (71.41) | (25.36) | (26.03) | (38.40) | (43.55) | (36.52) | (52.82) | (95.88) | (75.36) | (94.4) pt | |||||
| ROIC | — | 0.00 | (1,808.70) | (551.58) | (2,397.46) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 4.57 | 223.09 | (34.90) | (26.90) | (40.69) | (47.62) | (39.72) | (59.64) | (126.98) | (93.20) | (131.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 20 | 22 | 34 | 54 | 60 | 103 | 164 | 156 | — | +34.1% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Cabaletta Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio, Inc. | $280.4M | — (loss-making) | — | — | n/m | −35.72% (below 0%: shrinking) | 0.00% | 0.00% | |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VNDA Vanda Pharmaceuticals Inc. | $231.0M | — (loss-making) | — (loss-making) | +24.10% (above 0%: growing) | n/m | +9.57% (above 0%: growing) | 94.05% | (33.69%) | Compare |
| ACIU AC Immune | $227.0M | — (loss-making) | — (loss-making) | +152.31% (above 0%: growing) | n/m | +4.66% (above 0%: growing) | 100.00% | (302.13%) | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $222.7M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $202.5M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $199.8M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| Median of peers | $225.0M | — | — | +9.18% | — | +9.27% | 97.03% | (76.83%) |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.94m | 1.65m | 23.68 |
| 2024 | 8.10m | (8.63m) | 24.54 |
| 2023 | 4.81m | 14.47m | 245.41 |
Ownership
Directors and executive officers, together
6.44%
Entities associated with Prudential Financial, Inc.
11.30%
Bain Capital Life Sciences Opportunities III, LP
9.99%
Adage Capital Partners, L.P.
9.99%
T. Rowe Price Investment Management, Inc.
8.86%
Entities affiliated with Cormorant Asset Management, LP
8.08%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement